Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 113.44M P/E - EPS this Y -2,700.00% Ern Qtrly Grth -
Income -569k Forward P/E -1.86 EPS next Y -50.00% 50D Avg Chg -
Sales 101.21M PEG 6.62 EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book N/A EPS next 5Y -0.90% 52W High Chg -43.00%
Recommedations 2.90 Quick Ratio 1.14 Shares Outstanding 67.73M 52W Low Chg 46.00%
Insider Own 1.19% ROA -1.75% Shares Float 53.83M Beta 1.03
Inst Own 48.52% ROE - Shares Shorted/Prior 3.59M/3.53M Price 1.71
Gross Margin 100.00% Profit Margin -0.56% Avg. Volume 379,900 Target Price 2.90
Oper. Margin -2.28% Earnings Date May 7 Volume 196,695 Change 1.18%
About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc. News
04/25/24 Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
04/08/24 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
04/03/24 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
03/21/24 CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
03/18/24 CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
03/13/24 CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
03/12/24 CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
03/12/24 Q4 2023 CytomX Therapeutics Inc Earnings Call
03/11/24 CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update
03/11/24 CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
03/11/24 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
03/04/24 CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
02/27/24 CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
02/27/24 CytomX Therapeutics to Present at Upcoming March Investor Conferences
02/13/24 CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29%
01/24/24 Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
01/24/24 Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
01/24/24 CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
01/23/24 Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
01/23/24 Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
CTMX Chatroom

User Image Dude34 Posted - 23 hours ago

$CTMX dude, activate spellcheck .🤣 this is the 2nd time.

User Image BuyingSheep Posted - 1 day ago

@BioMan122 For somebody who is no longer invested nor interested, you have quite a lot of emotions on this stock $CTMX.

User Image BioMan122 Posted - 1 day ago

$CTMX everyone had the chance to get out

User Image BioMan122 Posted - 1 day ago

$CTMX total desaster

User Image Gator5326 Posted - 1 day ago

$CTMX

User Image BioMan122 Posted - 2 days ago

$CTMX i do not even feel in need to get in at these levels. i wait for much lower levels…

User Image BioMan122 Posted - 2 days ago

$CTMX low. lower. ctmx.

User Image LabPsycho Posted - 3 days ago

$CTMX @BioMan122 The problem I see with your strategy of trying to buy back down below ~$1.40 is while it looks like it could get there, it probably wont, then start creeping up, then perhaps another deal with big pharma and boom up $1 or more that day. But hang in there you might get lucky over the summer as many of these biotechs that have given up 50% in a few weeks may give up another 50% in a few months

User Image BioMan122 Posted - 4 days ago

$CTMX seems this will end red once again

User Image Dude34 Posted - 6 days ago

$CTMX picked up more today @1.69.. see you at the top. i dont care how long it takes

User Image BioMan122 Posted - 1 week ago

$CTMX nearly all of the recent gains lost already. exactly like i assumed some time ago. all just my opinion…

User Image BioMan122 Posted - 1 week ago

$CTMX some claimed to know about the dynamics. i hope those was all out early. i will buy very cheap soon then make another 100% here 😎

User Image LabPsycho Posted - 1 week ago

$CTMX Many little biotechs have given up almost 50% in a few weeks (BCAB PRLD ANNX off the top of my head for example), so by comparison CTMX not as bad. However, they better come up with another huge deal with an existing or new partner. For Pete's sake, they are in the same building as HARP when it was recently bought out for $680M and Amgen, AbbVie and other biggies are within a block or two of CTMX headquarters. One would think that on a weekly basis at least casual contacts are made between the managements of these companies at one of the nearby cafes / coffee shops.

User Image haily_haily Posted - 1 week ago

$CTMX what the hell??

User Image Gator5326 Posted - 1 week ago

$CTMX What happened?

User Image NoGainer1 Posted - 1 week ago

$CTMX story des jahres 2023 ;D

User Image BioMan122 Posted - 1 week ago

$CTMX what did i say? who is laughing now?

User Image ViractaTrader77 Posted - 1 week ago

ADC Buying Spree… Sutro Biopharma up next? https://www.labiotech.eu/trends-news/antibody-drug-conjugates-investment-surge/ $STRO $CTMX $BOLT $XNCR

User Image Brisse89 Posted - 1 week ago

$CTMX this one looks interesting

User Image ViractaTrader77 Posted - 1 week ago

$VINC $IMNM Key in ADC Space is to own a basket. https://twitter.com/BiotechTVHQ/status/1775900116924448891/mediaViewer?currentTweet=1775900116924448891&currentTweetUser=BiotechTVHQ $BOLT $CTMX

User Image Dude34 Posted - 2 weeks ago

$CTMX yup

User Image LabPsycho Posted - 2 weeks ago

$CTMX Is something brewing...why the huge volume a few days ago and now up in a huge Dow down day?

User Image LabPsycho Posted - 2 weeks ago

$CTMX Will any of CTMX partners - Moderna, Amgen, Astellas, Regeneron, or Bristol Myers Squibb panic buy CTMX and pull a Vertex (who bought Alpine Immune Sciences for almost $5Billion yesterday)?

User Image LabPsycho Posted - 2 weeks ago

$CTMX @BioMan122 I think you scared yourself out of this. Look at JANX market cap and tech compared to $CTMX and partners

User Image BioMan122 Posted - 2 weeks ago

$CTMX what did i say? 😂

User Image BioMan122 Posted - 2 weeks ago

$CTMX free fall now like i assumed. i think the worst is still ahead of us. i think it may probably even lose nearly all of its recent gains until maybe one day we will rise again. it is just my thoughts here…

User Image BioMan122 Posted - 2 weeks ago

$CTMX in my opinion this could fall to 1.30 range. personally i am all out now. good luck all. maybe buying again at much lower price…

User Image LabPsycho Posted - 2 weeks ago

$XLO Valuation Comparisons? IMO, buying a little biotech hoping for a take over rarely pans out. However, Considering : 1. In 2021 AbbVie exercised its exclusive right to acquire TeneoOne Earlier abbvie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody; 2. In 2024 Merck acquired Harpoon Therapeutics (working on masking / prodrug T-cell engagers (some similarities to XLO) for $680 million; 3. $CTMX (also working on masking antibodies) has several partnerships with huge pharma worth billions; 4. Pfizer recently paid LVTX a $7 million milestone for one of their bispecific gamma delta T cell engagers (up to $680M in future milestones) 5. Upcoming catalysts in the next months, so I think $XLO has room to run.

User Image LabPsycho Posted - 2 weeks ago

$XLO IMO, buying a little biotech hoping for a take over rarely pans out. However, Considering 1. In 2021 AbbVie exercised its exclusive right to acquire TeneoOne Earlier abbvie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody. 2. In 2024 Merck acquired Harpoon Therapeutics (working on masking / prodrug T-cell engagers (some similarities to XLO) for $680 million 3. $CTMX (also working on masking antibodies) has several partnerships with huge pharma worth billions. 4. Pfizer recently paid LVTX a $7 million milestone for one of their bispecific gamma delta T cell engagers (up to $680M in future milestones) I think $XLO has room to run.

User Image LabPsycho Posted - 2 weeks ago

$CTMX @Gator5326 Nice post. I have great expectations for CX-2051

Analyst Ratings
JP Morgan Neutral Apr 22, 24
BMO Capital Market Perform Mar 12, 24
Wedbush Neutral Mar 12, 24
Wedbush Neutral Nov 9, 23
Wedbush Outperform Nov 8, 23
BMO Capital Market Perform Aug 9, 23
Mizuho Neutral Mar 28, 23
BMO Capital Market Perform Jan 6, 23
BMO Capital Market Perform Nov 14, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BELVIN MARCIA SVP, Chief Scientifi.. SVP, Chief Scientific Officer Sep 20 Sell 1.3 4,119 5,355 147,951 09/22/23
Landau Jeffrey B Chief Business Offic.. Chief Business Officer Sep 20 Sell 1.3 4,119 5,355 76,379 09/22/23
McCarthy Sean A. CEO CEO Sep 20 Sell 1.3 14,601 18,981 430,755 09/22/23
ROWLAND LLOYD A General Counsel General Counsel Sep 20 Sell 1.3 5,486 7,132 80,609 09/22/23
McCarthy Sean A. CEO CEO May 19 Option 1.5749 16,535 26,041 405,356 05/23/23
Jones Elaine V Director Director Mar 29 Buy 1.55 5,000 7,750 5,142 03/31/23
Ogden Christopher SVP, Finance and Acc.. SVP, Finance and Accounting Mar 16 Sell 1.9793 516 1,021 37,772 03/20/23
Campoy Carlos Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 1.9791 1,748 3,459 38,224 03/20/23
McCarthy Sean A. CEO CEO Mar 16 Sell 1.8805 7,121 13,391 388,821 03/20/23
ROWLAND LLOYD A General Counsel General Counsel Mar 16 Sell 1.979 2,037 4,031 71,095 03/20/23
Landau Jeffrey B Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 1.9792 1,477 2,923 69,248 03/20/23
Peterson Amy C. EVP, Chief Developme.. EVP, Chief Development Officer Mar 16 Sell 1.979 4,257 8,425 58,433 03/20/23
McCarthy Sean A. President and CEO President and CEO May 09 Option 0.95 90,931 86,384 265,853 05/11/22
McCarthy Sean A. President and CEO President and CEO Jun 16 Option 1.04 40 42 7,849 06/16/21
McCarthy Sean A. President and CEO President and CEO Apr 02 Option 1.13 100,000 113,000 306,894 04/02/21